Mevastatin-CAS 73573-88-3-Calbiochem

C₂₃H₃₄O₅

390.51

MFCD05662341

An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppressing Ras farnesylation. Inhibitor of myoblast fusion. Also may induce bone morphogenic protein-2 (BMP-2). Causes cell cycle arrest in late G₁ phase.
This is an inactive form which may require activation for use with isolated cells depending upon the application. To activate, treat with NaOH in ethanol and then neutralize to pH 7.2.
An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppresses Ras farnesylation. Inhibitor of myoblast fusion. Causes cell cycle arrest in late G₁ phase. May induce bone morphogenic protein-2 (BMP-2). This product requires activation for use in cell culture and cell-free assay systems. To activate, treat with ethanol solution with 1 N NaOH and then neutralize with 1 N HCl to pH 7.2 (see Keyomarsi, K . et al. 1991).

Primary Target
HMG-CoA reductase
Product does not compete with ATP.
Reversible: no
Cell permeable: no

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.

Sugiyama, M., et al. 2000. Biochem. Biophys. Res. Commun.271, 688.
Hug, T., et al. 1995. Pflugers Archiv. Eur. J. Physiol.429, 682.
Belo, R.S., et al. 1993. Mol.Cell. Biochem.126, 159.
McLeish, K.R., et al. 1993. Biochem. Biophys. Res. Commun.197, 763.
Keyomarsi, K., et al. 1991. Cancer Res. 51, 3602.
Jackson, J.H., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 3042.
Kita, T., et al. 1980. J. Clin. Invest. 66, 1094.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥95% (HPLC)

solid

Calbiochem^®

OK to freeze

white

ethanol: soluble

ambient

2-8℃

1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1

AJLFOPYRIVGYMJ-INTXDZFKSA-N

50 mg in Plastic ampoule

11 - Combustible Solids

WGK 3